Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will showcase its technology at the upcoming HRX digital health conference from September 4-6, 2025, in Atlanta.

CEO David Fischel will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Following this, at 4:45 PM EDT, a panel of electrophysiologists will lead a session titled "Cutting-Edge Ablation Techniques That Challenge Traditional Methods and Improve Patient Outcomes", exploring robotics, AR/VR, AI, and automation in cardiac care.

The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.

ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine.

Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5^th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper, Prof. Sabine Ernst, Dr. Devi Nair, and Dr. Peter Weiss, will lead a session titled “Cutting-Edge Ablation Techniques That Challenge Traditional Methods and Improve Patient Outcomes”. The session explores the role of robotics, augmented and virtual reality, AI, and automation in improving care for heart rhythm patients.

“We appreciate the opportunity to join the HRX community as we jointly define a more advanced, digital and robotic future for the electrophysiology field,” said David Fischel.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

When and where will Stereotaxis (STXS) present at HRX 2025?

Stereotaxis will present at HRX on September 5th, 2025, with CEO David Fischel participating in a roundtable at 3:45 PM EDT, followed by an expert panel session at 4:45 PM EDT in Atlanta, Georgia.

How many patients have been treated using Stereotaxis (STXS) technology?

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.

What topics will be discussed at the Stereotaxis (STXS) HRX 2025 panel session?

The panel session will discuss cutting-edge ablation techniques, focusing on robotics, augmented and virtual reality, AI, and automation in improving care for heart rhythm patients.

Who are the key speakers at the Stereotaxis (STXS) HRX 2025 presentation?

Key speakers include CEO David Fischel and a panel of electrophysiologists: Dr. Daniel Cooper, Prof. Sabine Ernst, Dr. Devi Nair, and Dr. Peter Weiss.

What is the main focus of Stereotaxis (STXS) as a company?

Stereotaxis is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention, focusing on robotic systems, instruments, and information solutions for the interventional laboratory.